Dianthus Therapeutics Q3 2026 net loss widens 27% to $46.64 million

Bitget2026/11/04 21:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dianthus Therapeutics’ third-quarter 2026 net loss widened 27% from a year earlier to $46.64 million.
License revenue more than tripled to $1.21 million, while research and development expenses rose 40% to $45.6 million.
Cash, cash equivalents and investments totaled approximately $1.2 billion at September 30, providing projected runway into 2030.
Claseprubart’s Phase 2 MMN trial results remain expected in December 2026, with a Phase 3 trial planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041601PRIMZONEFULLFEED9870324) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dianthus Therapeutics Q3 2026 net loss widens 27% to $46.64 million

You may also like

Crypto prices